EA028402B1 - Хинолоновые производные - Google Patents

Хинолоновые производные Download PDF

Info

Publication number
EA028402B1
EA028402B1 EA201591195A EA201591195A EA028402B1 EA 028402 B1 EA028402 B1 EA 028402B1 EA 201591195 A EA201591195 A EA 201591195A EA 201591195 A EA201591195 A EA 201591195A EA 028402 B1 EA028402 B1 EA 028402B1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydroxy
oxo
dihydroquinoline
alkyl
carboxamido
Prior art date
Application number
EA201591195A
Other languages
English (en)
Russian (ru)
Other versions
EA201591195A1 (ru
Inventor
Ранджит К. Десаи
Враджеш Пандия
Панкадж Р. Пател
Original Assignee
Кадила Хелзкэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA028402(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кадила Хелзкэр Лимитед filed Critical Кадила Хелзкэр Лимитед
Publication of EA201591195A1 publication Critical patent/EA201591195A1/ru
Publication of EA028402B1 publication Critical patent/EA028402B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
EA201591195A 2012-12-24 2013-12-23 Хинолоновые производные EA028402B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3600MU2012 2012-12-24
PCT/IN2013/000796 WO2014102818A1 (en) 2012-12-24 2013-12-23 Novel quinolone derivatives

Publications (2)

Publication Number Publication Date
EA201591195A1 EA201591195A1 (ru) 2015-10-30
EA028402B1 true EA028402B1 (ru) 2017-11-30

Family

ID=54148255

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591195A EA028402B1 (ru) 2012-12-24 2013-12-23 Хинолоновые производные

Country Status (26)

Country Link
US (1) US9394300B2 (enExample)
EP (1) EP2935221B1 (enExample)
JP (1) JP6026013B2 (enExample)
KR (1) KR101733901B1 (enExample)
CN (1) CN104903295B (enExample)
AP (1) AP2015008502A0 (enExample)
AR (1) AR094300A1 (enExample)
AU (1) AU2013368843B2 (enExample)
BR (1) BR112015014222B1 (enExample)
CA (1) CA2894636C (enExample)
CL (1) CL2015001802A1 (enExample)
EA (1) EA028402B1 (enExample)
ES (1) ES2660288T3 (enExample)
IL (1) IL239109B (enExample)
JO (1) JO3781B1 (enExample)
MA (1) MA38138A1 (enExample)
MX (1) MX373392B (enExample)
MY (1) MY175854A (enExample)
NZ (1) NZ708605A (enExample)
PH (1) PH12015501452B1 (enExample)
SG (1) SG11201504458XA (enExample)
TR (1) TR201802305T4 (enExample)
TW (1) TWI598339B (enExample)
UA (1) UA117122C2 (enExample)
WO (1) WO2014102818A1 (enExample)
ZA (1) ZA201503814B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2959688C (en) * 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
JP7142406B2 (ja) 2017-05-09 2022-09-27 カインド ファーマシューティカル インドリジン誘導体及びその医学的応用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
TW202200547A (zh) * 2020-03-13 2022-01-01 印度商卡地拉保健有限公司 喹啉酮化合物的新穎鹽類
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2021240454A1 (en) * 2020-05-29 2021-12-02 Cadila Healthcare Limited Treatment for psoriasis and skin inflammatory diseases
WO2021245533A1 (en) * 2020-06-01 2021-12-09 Cadila Healthcare Limited Treatment for the inflammatory bowel disease
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
BR112023018949A2 (pt) 2021-03-19 2023-10-17 Zydus Lifesciences Ltd Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto
EP4308089A4 (en) * 2021-03-19 2025-02-26 Zydus Lifesciences Limited QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION
WO2022238745A1 (en) * 2021-05-14 2022-11-17 Zydus Lifesciences Limited Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113549011B (zh) * 2021-08-10 2023-05-09 广东东阳光药业有限公司 德度司他的共晶或盐及其制备方法和用途
CN117836275A (zh) * 2021-09-20 2024-04-05 载度思生命科学有限公司 德度司他颗粒及其组合物
WO2023248193A1 (en) * 2022-06-24 2023-12-28 Zydus Lifesciences Limited Treatment for glomerular diseases
WO2024028744A1 (en) * 2022-08-01 2024-02-08 Zydus Lifesciences Limited Treatment for aplastic anemia (aa)
KR20260061246A (ko) 2023-10-24 2026-05-06 카인드 파마슈티컬 저산소증 유도인자-프로릴히드록시라제 억제제를 함유하는 장시간 작용형 경구 의약품 및 그 사용
WO2026018268A1 (en) * 2024-07-13 2026-01-22 Zydus Lifesciences Limited Treatment of diabetes and diabetes induced ckd and the associated symptoms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2008138060A1 (en) * 2007-05-16 2008-11-20 Cowper Norman T System and method for maximising solids concentration of slurry pumped through a pipeline

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8703795B2 (en) * 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
AU2007234408B2 (en) * 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
JP2009537558A (ja) * 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
WO2008010964A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2142509B1 (en) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008130527A1 (en) * 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
US8030346B2 (en) * 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
CA2685219C (en) * 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
JP2011505367A (ja) * 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
CN101951775A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢噻吩并吡啶
CN101951776A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢-1h-吡咯稠合吡啶酮
CA2716798A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
US20110098324A1 (en) * 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
US8283465B2 (en) 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
CN102574805A (zh) * 2009-08-20 2012-07-11 维福（国际）股份公司 新型喹啉铁调素拮抗剂
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
EP2758058B1 (en) 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituted pyrimidines
US20150018546A1 (en) * 2012-01-31 2015-01-15 Toyama Chemical Co., Ltd. Heterocyclic compound having anti-hiv activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2008138060A1 (en) * 2007-05-16 2008-11-20 Cowper Norman T System and method for maximising solids concentration of slurry pumped through a pipeline

Also Published As

Publication number Publication date
CN104903295A (zh) 2015-09-09
AR094300A1 (es) 2015-07-22
AP2015008502A0 (en) 2015-06-30
US20150299193A1 (en) 2015-10-22
UA117122C2 (uk) 2018-06-25
AU2013368843A1 (en) 2015-06-18
KR20150085535A (ko) 2015-07-23
EP2935221A1 (en) 2015-10-28
IL239109B (en) 2019-07-31
ES2660288T3 (es) 2018-03-21
JP6026013B2 (ja) 2016-11-16
CA2894636C (en) 2018-04-03
AU2013368843B2 (en) 2016-02-25
NZ708605A (en) 2016-07-29
IL239109A0 (en) 2015-07-30
CN104903295B (zh) 2017-09-01
SG11201504458XA (en) 2015-07-30
US9394300B2 (en) 2016-07-19
HK1211022A1 (en) 2016-05-13
MA38138A1 (fr) 2016-11-30
TWI598339B (zh) 2017-09-11
MX373392B (es) 2020-04-20
CA2894636A1 (en) 2014-07-03
JO3781B1 (ar) 2021-01-31
EP2935221B1 (en) 2018-02-07
BR112015014222A2 (pt) 2017-07-11
WO2014102818A1 (en) 2014-07-03
PH12015501452A1 (en) 2015-09-21
BR112015014222B1 (pt) 2022-12-06
CL2015001802A1 (es) 2015-10-02
EA201591195A1 (ru) 2015-10-30
TW201441196A (zh) 2014-11-01
KR101733901B1 (ko) 2017-05-08
ZA201503814B (en) 2016-05-25
MX2015008233A (es) 2015-09-29
JP2016503052A (ja) 2016-02-01
PH12015501452B1 (en) 2018-06-06
MY175854A (en) 2020-07-14
TR201802305T4 (tr) 2018-03-21

Similar Documents

Publication Publication Date Title
US9394300B2 (en) Quinolone derivatives
ES2964964T3 (es) Compuestos bicíclicos puenteados como moduladores del receptor X farnesoide
WO2023062575A1 (en) Cyclic vinyl sulfone compounds as wrn inhibitors
KR102885020B1 (ko) 벤조티오펜 화합물, 이의 제조 방법 및 용도
KR20210028144A (ko) Atf6 저해제 및 그의 용도
KR20070072554A (ko) 카르바졸 유도체, 그 용매화물, 또는 약학적으로 허용되는그 염
JP6768083B2 (ja) 抗腫瘍剤およびブロモドメイン阻害剤
KR20160067841A (ko) 헤테로사이클릭 화합물 및 사용 방법
CN114258391A (zh) 吡咯化合物
KR20230079427A (ko) 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조
CN110914248A (zh) 含有胺或(硫代)酰胺的lxr调节剂
CN112513011A (zh) 苯衍生物
HK1211022B (en) Quinolone derivatives
CN112110944B (zh) 一种化合物及其制备方法和应用
JP2009519322A (ja) ｐ３８ＭＡＰキナーゼインヒビターとしてのスルホキシイミン誘導体
HK40048484A (en) Benzene derivative
OA17332A (en) Novel quinolone derivatives.
CN113710666A (zh) 半胱天冬酶抑制剂的前药

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM